騰訊(00700.HK)有份投資 線上保險初創水滴開始預路演
據路透旗下《IFR》報道,騰訊(00700.HK)有份投資的互聯網保險初創水滴公司已就其美國IPO,夥高盛、大摩及美銀開始預路演,早前據報公司擬籌5億美元(下同),估值達40-60億元,不過據上周五遞文的文件則顯示公司擬籌1億元。
報道引述消息人士指,在近期科技股捱沽後,水滴未有決定融資規模或估值目標,同時公司業務亦有所轉變,於3月或水滴應內地收緊金融科技監管,終止了線上醫療健康援助計劃,相關平台服務約8,000萬名用戶。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.